- Home
- CYTH vs COCP Comparison
CYTH vs COCP Comparison
Compare CYTH & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTH
- COCP
- Stock Information
- Founded
- CYTH 1990
- COCP N/A
- Country
- CYTH United States
- COCP United States
- Employees
- CYTH N/A
- COCP N/A
- Industry
- CYTH Biotechnology: Pharmaceutical Preparations
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- CYTH Health Care
- COCP Health Care
- Exchange
- CYTH Nasdaq
- COCP Nasdaq
- Market Cap
- CYTH 20.4M
- COCP 18.3M
- IPO Year
- CYTH N/A
- COCP N/A
- Fundamental
- Price
- CYTH $0.63
- COCP $2.17
- Analyst Decision
- CYTH Buy
- COCP Strong Buy
- Analyst Count
- CYTH 3
- COCP 1
- Target Price
- CYTH $0.95
- COCP $7.00
- AVG Volume (30 Days)
- CYTH 43.6K
- COCP 24.1K
- Earning Date
- CYTH 11-14-2024
- COCP 11-13-2024
- Dividend Yield
- CYTH N/A
- COCP N/A
- EPS Growth
- CYTH N/A
- COCP N/A
- EPS
- CYTH N/A
- COCP N/A
- Revenue
- CYTH $870,725.00
- COCP N/A
- Revenue This Year
- CYTH N/A
- COCP N/A
- Revenue Next Year
- CYTH $24.49
- COCP N/A
- P/E Ratio
- CYTH N/A
- COCP N/A
- Revenue Growth
- CYTH N/A
- COCP N/A
- 52 Week Low
- CYTH $0.57
- COCP $1.33
- 52 Week High
- CYTH $2.12
- COCP $3.10
- Technical
- Relative Strength Index (RSI)
- CYTH 46.82
- COCP 65.05
- Support Level
- CYTH $0.60
- COCP $1.90
- Resistance Level
- CYTH $0.69
- COCP $1.99
- Average True Range (ATR)
- CYTH 0.04
- COCP 0.17
- MACD
- CYTH 0.00
- COCP 0.02
- Stochastic Oscillator
- CYTH 50.00
- COCP 84.62
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).